Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema
NCT ID: NCT00488241
Last Updated: 2023-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2007-06-30
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
NCT01012453
Hand Eczema in the Health Care Sector
NCT04449575
Methotrexat to Hand Eczema in the BIOSKIN Cohort
NCT07338305
A 24-week Single-blind Trial of Prevention of Hand Eczema in Cleaners
NCT05763914
Occupational Hand Eczema - Testing of a Prevention-concept
NCT04790799
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Topically applied daily for 2 weeks
Zarzenda
Topically applied daily for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zarzenda
Topically applied daily for 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 4 weeks have passed since use of systemic treatment for eczema
* At least 4 weeks have passed since any vaccination
* At least 1 week has passed since last topic treatment on hands with corticosteroids
* Agree to use adequate contraceptive method if of childbearing potential
* Willingness to avoid excessive exposure to sunlight and avoid skin irritants
Exclusion Criteria
* Severe excoriations on the hands
* Need for systemic treatment for atopic dermatitis
* Known sensitivity to Zarzenda and/or to extract of nut butyrospermum parkii (shea)
* Known immune deficiency
* Concomitant infection on hands
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intendis GmbH
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401663
Identifier Type: -
Identifier Source: org_study_id
NCT01646658
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.